JBM Healthcare (HKG: 2161) reported a profit attributable to the equity shareholders of around HK$130.5 million for the year ended March 31, 2024, as compared to HK$57.1 million from the previous fiscal year, a Tuesday filing with the Hong Kong Exchange said.
The companyâs earnings per share for the fiscal year 2024 came in at HK$0.1476 as compared to HK$0.0641 from the previous fiscal year.
The companyâs revenue for the reporting period was about HK$648.4 million, higher than the revenue of HK$520.3 million for the previous fiscal year, mainly attributable to a notable increase in revenues from the companyâs branded medicine segment, Chinese medicine segment, and health and Wellness products.
The company proposed a final dividend of HK$0.0405 per share for the year.